Aclaris Therapeutics (ACRS) Treasury Shares (2014 - 2026)
Aclaris Therapeutics (ACRS) posted quarterly Treasury Shares of $1.9 million for Q1 2026, down 41.66% year-over-year from $3.2 million in Q1 2025, and down 15.04% quarter-over-quarter from $2.2 million in Q4 2025.
Aclaris Therapeutics (ACRS) Treasury Shares (2014 - 2026) Analysis & Trends
Aclaris Therapeutics' Treasury Shares history runs 9 years deep, the most recent figure standing at $1.9 million for Q1 2026.
- In Q1 2026, Treasury Shares fell 41.66% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $1.9 million (down 41.66% YoY), while the FY2025 annual figure was $2.2 million, up 3.99% from the prior year.
- Treasury Shares for Q1 2026 stood at $1.9 million, down from $2.2 million in the prior quarter.
- The five-year high for Treasury Shares was $3.2 million in Q1 2025, with the low at $2375.0 in Q2 2022.
- The 5-year median for Treasury Shares is $1.7 million (2023), against an average of $1.8 million.
- The sharpest annual moves came in 2022 and 2023: Treasury Shares sank 99.84% in 2022, then surged 72322.74% in 2023.
- Aclaris Therapeutics' Treasury Shares stood at $1.5 million in 2022, then climbed by 0.08% to $1.5 million in 2023, then surged by 37.73% to $2.1 million in 2024, then advanced by 3.99% to $2.2 million in 2025, then retreated by 15.04% to $1.9 million in 2026.
- Business Quant data shows ACRS's Treasury Shares at $1.9 million in Q1 2026, $2.2 million in Q4 2025, and $241840.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | 1.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.87 Mn |
| Jun 30, 2026 | 1.87 Mn |
| Mar 31, 2026 | 1.85 Mn |
| Mar 31, 2026 | 1.85 Mn |
| Dec 31, 2025 | 2.18 Mn |
| Dec 31, 2025 | 2.18 Mn |
| Sep 30, 2025 | 241,840.00 |
| Sep 30, 2025 | 241,840.00 |
| Jun 30, 2025 | 69,480.00 |
| Jun 30, 2025 | 69,480.00 |
| Mar 31, 2025 | 3.17 Mn |
| Mar 31, 2025 | 3.17 Mn |
| Dec 31, 2024 | 2.10 Mn |
| Dec 31, 2024 | 2.10 Mn |
| Sep 30, 2024 | 3.07 Mn |
| Sep 30, 2024 | 3.07 Mn |
| Jun 30, 2024 | 3.11 Mn |
| Jun 30, 2024 | 3.11 Mn |
| Mar 31, 2024 | 3.14 Mn |
| Mar 31, 2024 | 3.14 Mn |